Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Purepac gabapentin approval on hold

Executive Summary

Purepac/Teva will not be able to market gabapentin capsules before December unless the companies reach an agreement with Apotex to settle a lawsuit challenging generic exclusivity rights to Pfizer's Neurontin. A federal appeals court granted Apotex' request to stay the ANDA approval of "first filer" Purepac pending resolution of Apotex' lawsuit against FDA. Purepac received approval in September 2003 but has not yet launched due to pending litigation; the company has selectively waived its 180-day exclusivity to Teva. The court's decision does not affect approvals Ivax has on tablet forms of gabapentin; Ivax says it is still considering when to launch...

You may also be interested in...



Alpharma Generic Exclusivity Deals Will Face FTC Scrutiny Under Settlement

Alpharma has agreed to limits on future agreements with generic companies involving licensing of 180-day "first-to-file" exclusivity as part of a settlement with the Federal Trade Commission

Grail Starts PATHFINDER Trial To Evaluate Multi-Cancer Blood Test For Early Cancer Detection

Grail announced it will enroll about 6,200 people in an interventional, multi-center study evaluating its multi-cancer early-detection blood test. This is the first time health care providers will use this test to help guide patient care.

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Topics

UsernamePublicRestriction

Register

PS044440

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel